WO2000007623A1 - Vaccin combine d'immunoprophylaxie contre l'hepatite virale b et d, le tetanos, la diphterie et la coqueluche - Google Patents

Vaccin combine d'immunoprophylaxie contre l'hepatite virale b et d, le tetanos, la diphterie et la coqueluche Download PDF

Info

Publication number
WO2000007623A1
WO2000007623A1 PCT/RU1999/000265 RU9900265W WO0007623A1 WO 2000007623 A1 WO2000007623 A1 WO 2000007623A1 RU 9900265 W RU9900265 W RU 9900265W WO 0007623 A1 WO0007623 A1 WO 0007623A1
Authority
WO
WIPO (PCT)
Prior art keywords
amount
vaccine
pertussis
diphtheria
tetanus
Prior art date
Application number
PCT/RU1999/000265
Other languages
English (en)
Russian (ru)
Inventor
Vera Nikolaevna Borisova
Vladimir Alexeevich Melnikov
Mikhail Valentinovich Budanov
Irina Mikhailovna Yakovleva
Veniamin Filippovich Petrov
Nina Pavlovna Efimova
Alevtina Maximovna Nikolaeva
Elena Valentinovna Pushkareva
Diana Vasiliyevna Gryaznova
Original Assignee
Aktsionernoe Obschestvo Zakrytogo Tipa Nauchno-Proizvodstvennaya Kompaniya 'combiotech Ltd.'
Permskoe Nauchno-Proizvodstvennoe Obiedinenie 'biomed'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20208734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000007623(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aktsionernoe Obschestvo Zakrytogo Tipa Nauchno-Proizvodstvennaya Kompaniya 'combiotech Ltd.', Permskoe Nauchno-Proizvodstvennoe Obiedinenie 'biomed' filed Critical Aktsionernoe Obschestvo Zakrytogo Tipa Nauchno-Proizvodstvennaya Kompaniya 'combiotech Ltd.'
Publication of WO2000007623A1 publication Critical patent/WO2000007623A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
    • C12N2760/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the invention is subject to the field of medicine, and it is the name of the clinical immunology that affects the development and use of new types of complex infections in patients with obstructive diseases.
  • a combined vaccine is known to contain antigens that protects against several diseases, such as dysfunctions, ankylosing spondylitis, acute bowel disease, and acute blood fever.
  • the objective of the invention is the development of a new complex product for simultaneous effective treatment of the disease, ⁇ ⁇ 00/07623 ⁇ / ⁇ 9 / 00265
  • the posed problem was solved by means of consummation of the combined vaccine for the immunodeficiency of the viral hepatitis ⁇ and D.
  • the vaccine contains antigens of the viral virus ⁇ , pox, diphtheria and rodent, and also adjuvant.
  • a vaccine is different in that it is available in ⁇ 5 of a genuine dose in the quality of the antigens:
  • FCS 42-3362-97 which regulates various indices of antigens, for a malignant-diffuse-tetanus vaccine. Is ⁇ lzuemy in s ⁇ s ⁇ ave ⁇ ve ⁇ n ⁇ s ⁇ ny an ⁇ igen vi ⁇ usa ge ⁇ a ⁇ i ⁇ a ⁇ ( ⁇ ), isolated from sh ⁇ amma- ⁇ dutsen ⁇ a ⁇ .sege ⁇ ae yavlyae ⁇ sya ⁇ a ⁇ zhe izves ⁇ nym and s ⁇ s ⁇ b eg ⁇ ⁇ lucheniya ⁇ isan in ⁇ a ⁇ en ⁇ e ⁇ ⁇ 2088664.
  • ⁇ n ⁇ igen v ⁇ di ⁇ in s ⁇ s ⁇ av is ⁇ lzuem ⁇ y in nas ⁇ yashee v ⁇ emya for immun ⁇ ila ⁇ i ⁇ i ge ⁇ a ⁇ i ⁇ a ⁇ va ⁇ tsiny ge ⁇ a ⁇ i ⁇ a ⁇ Recombinant yeast liquid ( ⁇ C 42-3438-97).
  • the method of obtaining a combined vaccine is concluded in the usual mixture of the components of the composition, and with this modality ⁇ ⁇ 00/07623 ⁇ 99 / 00265
  • the SDS is assembled on an aluminum gel, taking all of its quantities indicated in the formula, after which
  • the scope of the distribution of the differential analyzer accounted for the disruption of the communication, the transmission of the immune system is responsible for the communication of 25
  • EXAMPLE 1 EXAMPLE 2 30 Antigen of the viral virus ⁇ ( ⁇ ), obtained by cultivating a transformed phantom of the strain ⁇ .
  • the index of the serial for the combined preparation is often much higher than that of the unit, which is much higher than that of the ⁇ ⁇ 00/07623 ⁇ 99 / 00265
  • the index of serialization for the combined preparation is partly higher than that of the preparation without the use of a dose and the use of it at a lower dose.
  • a developed medicinal form with a virus virus antigens can be used for immunosuppression of any known vaccine vaccine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention se rapporte au domaine de la médecine, plus précisément à celui de l'immunologie clinique, et concerne l'élaboration ainsi que l'utilisation d'une nouvelle préparation complexe d'immunoprophylaxie contre divers types d'infections simultanément. Cette invention concerne essentiellement l'utilisation de préparations d'immunoprophylaxie contre l'hépatite virale B et D, le tétanos, la diphtérie et la coqueluche. Cette invention concerne également un vaccin combiné d'immunoprophylaxie contre l'hépatite virale B et D, le tétanos, la diphtérie et la coqueluche, lequel vaccin contient leurs antigènes ainsi qu'un adjuvant. Ce vaccin se caractérise en ce qu'il contient également les éléments suivants en qualité d'antigènes pour une quantité de 1 ml: un antigène du virus de l'hépatite B (HBsAg) obtenu par la culture de cellules transformées de la souche S. cerevisiae VKPM Y-2203 dans une quantité de 5 à 10 νg; une anatoxine diphtérique purifiée et rendue non nocive dans une quantité de 10 à 20 Lf; une anatoxine tétanique purifiée et rendue non nocive dans une quantité de 5 à 10 EC; des microbes de la coqueluche tués par formaline dans une quantité de 10 à 15 OE; une quantité de 0,01 ± 0,002 % de merthiolate; un gel d'aluminium d'hydroxyde dans une quantité de 0,6 à 1,2 mg une fois transformé en aluminium; et jusqu'à 1,0 ml d'un solvant pharmaceutiquement acceptable. Ces préparations possèdent un taux élevé de séroconversion grâce à l'action promotrice réciproque des composants constituant la préparation.
PCT/RU1999/000265 1998-07-31 1999-07-30 Vaccin combine d'immunoprophylaxie contre l'hepatite virale b et d, le tetanos, la diphterie et la coqueluche WO2000007623A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU98114004A RU2130778C1 (ru) 1998-07-31 1998-07-31 Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
RU98114004 1998-07-31

Publications (1)

Publication Number Publication Date
WO2000007623A1 true WO2000007623A1 (fr) 2000-02-17

Family

ID=20208734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1999/000265 WO2000007623A1 (fr) 1998-07-31 1999-07-30 Vaccin combine d'immunoprophylaxie contre l'hepatite virale b et d, le tetanos, la diphterie et la coqueluche

Country Status (2)

Country Link
RU (1) RU2130778C1 (fr)
WO (1) WO2000007623A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835663A2 (fr) 1992-05-23 1998-04-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccins combinés contenant des antigènes de surface du virus de l'Hépatite B et d'autres antigènes
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
WO2012093406A2 (fr) 2011-01-05 2012-07-12 Bharat Biotech International Limited Vaccin heptavalent combiné
WO2020236973A1 (fr) 2019-05-20 2020-11-26 Soligenix, Inc. Compositions et procédés de fabrication de vaccins anti-filovirus trivalents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024148A1 (fr) * 1992-05-23 1993-12-09 Smithkline Beecham Biologicals (S.A.) Vaccins combines contenant des antigenes de surface du virus de l'hepatite b et d'autres antigenes
RU2088664C1 (ru) * 1996-01-26 1997-08-27 Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд." Рекомбинантная плазмидная днк pdes20, кодирующая поверхностный антиген вируса гепатита в (hbsag/ayw), штамм дрожжей saccharomyces cerevisiae, содержащий рекомбинантную плазмидную днк pdes20 - продуцент поверхностного антигена вируса гепатита в (hbsag/ayw)
US5747044A (en) * 1986-06-17 1998-05-05 Chiron Corporation Hepatitis delta diagnostics and vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747044A (en) * 1986-06-17 1998-05-05 Chiron Corporation Hepatitis delta diagnostics and vaccines
WO1993024148A1 (fr) * 1992-05-23 1993-12-09 Smithkline Beecham Biologicals (S.A.) Vaccins combines contenant des antigenes de surface du virus de l'hepatite b et d'autres antigenes
RU2088664C1 (ru) * 1996-01-26 1997-08-27 Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд." Рекомбинантная плазмидная днк pdes20, кодирующая поверхностный антиген вируса гепатита в (hbsag/ayw), штамм дрожжей saccharomyces cerevisiae, содержащий рекомбинантную плазмидную днк pdes20 - продуцент поверхностного антигена вируса гепатита в (hbsag/ayw)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rukovodstvo po vaktsinnomu i syvorotochnomu delu. Pod. red. (<<under editorship>>) P.N. Burgasova. M., Meditsina, 1978, lines 157-159. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835663A2 (fr) 1992-05-23 1998-04-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccins combinés contenant des antigènes de surface du virus de l'Hépatite B et d'autres antigènes
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
WO2012093406A2 (fr) 2011-01-05 2012-07-12 Bharat Biotech International Limited Vaccin heptavalent combiné
EP3459562A1 (fr) 2011-01-05 2019-03-27 Bharat Biotech International Limited Vaccin à combinaison heptavalent
WO2020236973A1 (fr) 2019-05-20 2020-11-26 Soligenix, Inc. Compositions et procédés de fabrication de vaccins anti-filovirus trivalents

Also Published As

Publication number Publication date
RU2130778C1 (ru) 1999-05-27

Similar Documents

Publication Publication Date Title
Sexton et al. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic
Emmons et al. A case of human rabies with prolonged survival
Carlsson et al. Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination
JPH08508247A (ja) 粘膜表面への免疫原の輸送における重合的粘膜付着体
CN102427828A (zh) 含具有信号肽的细菌毒素作为载体的半抗原-载体缀合物和它们在免疫原性组合物中的用途
KR20070110513A (ko) 알루미늄 포스페이트 및 3ｄ－ｍｐｌ을 포함하는 보조약조성물
CN101123982B (zh) 脂质和一氧化二氮组合作为用于增强疫苗功效的佐剂
TW201138805A (en) Composition of organic compounds
CN107469075B (zh) 一种高剂量四价流感疫苗组合物
BE1021315B1 (fr) Nouvelles compositions
US11596680B2 (en) Norovirus vaccine
WO2000007623A1 (fr) Vaccin combine d&#39;immunoprophylaxie contre l&#39;hepatite virale b et d, le tetanos, la diphterie et la coqueluche
Couch et al. Induction of immunity in man by crystalline adenovirus type 5 capsid antigens
CN102895188A (zh) 冰片-姜黄素脂质体及其制备方法与应用
ES2339035T3 (es) Tratamiento de enfermedades.
WO2010111586A2 (fr) Immunisation par voie muqueuse
CN107693788A (zh) 一种用于预防或治疗乙型肝炎的药物组合物及其用途
WO2017090766A1 (fr) Composition pharmaceutique de vaccin pour administration par voie orale, et procédé de fabrication de celle-ci
CN107929728A (zh) 一种肺炎球菌蛋白疫苗及其制备方法
JP2004508424A (ja) 免疫調節調剤物
Fouts et al. Liver-Gastric Tissue Preparations in the Treatment of Pernicious Anemia
TW202034950A (zh) 用於治療b型肝炎的藥物製劑及其製備方法和用途
US6905712B2 (en) Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
US20240123062A1 (en) Bivalent dengue/hepatitus b vaccines
Hendrickse et al. Measles vaccination with reduced dosage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BY DE KZ MD MN UA UZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642